MedPath

Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Non-small Cell Lung Cancer Stage IIIB/IV
Head and Neck Squamous Cell Carcinoma (HNSCC)
Colorectal Adenocarcinoma
Advanced Solid Tumors
Interventions
Drug: Chemotherapy
Drug: AK129(dose 1)
Drug: Cis-platinum
Drug: 5-FU (5-fluorouracil)
Drug: AK129(dose 2)
Drug: AK129(RP2D)
First Posted Date
2025-04-24
Last Posted Date
2025-04-24
Lead Sponsor
Akeso
Target Recruit Count
230
Registration Number
NCT06943820
Locations
🇨🇳

Liaoning Cancer Hospital, Shenyang, Liaoning, China

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Early Phase 1
Not yet recruiting
Conditions
CNS Embryonal Tumor
CNS, Medulloblastoma
Atypical Teratoid Rhabdoid Tumor
Medulloblastoma, Childhood
Medulloblastoma, Group 3
Medulloblastoma, Group 4
Pineoblastoma
Embryonal Tumor With Abundant Neuropil and True Rosettes
Ependymoblastoma
Medulloepithelioma
Interventions
Drug: Topotecan IT
First Posted Date
2025-04-24
Last Posted Date
2025-04-24
Lead Sponsor
C17 Council
Target Recruit Count
15
Registration Number
NCT06942039

Toripalimab With Chemotherapy for Sinus Cancer

Phase 2
Not yet recruiting
Conditions
Sinonasal Cancer
Paranasal Sinus Neoplasms
Squamous Cell Carcinoma
Sinonasal Undifferentiated Carcinoma
Locally Advanced Head and Neck Cancer
Interventions
Radiation: Radiation Therapy
First Posted Date
2025-04-23
Last Posted Date
2025-04-24
Lead Sponsor
Glenn J. Hanna
Target Recruit Count
20
Registration Number
NCT06940180
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Phase 4
Not yet recruiting
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
First Posted Date
2025-04-17
Last Posted Date
2025-04-23
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
50
Registration Number
NCT06931145
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2
Not yet recruiting
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
Drug: Albumin-Paclitaxel
First Posted Date
2025-04-15
Last Posted Date
2025-04-15
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
180
Registration Number
NCT06927180
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC.

Phase 3
Not yet recruiting
Conditions
EGFR-mutated Locally Advanced or Metastatic NSCLC
Interventions
First Posted Date
2025-04-15
Last Posted Date
2025-04-15
Lead Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Target Recruit Count
380
Registration Number
NCT06927986

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2
Not yet recruiting
Conditions
Breast Neoplasms
Interventions
Drug: Iza-bren
First Posted Date
2025-04-15
Last Posted Date
2025-05-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
560
Registration Number
NCT06926868
Locations
🇺🇸

Local Institution - 0303, Hot Springs, Arkansas, United States

🇺🇸

Local Institution - 0307, Cerritos, California, United States

🇺🇸

Local Institution - 0308, Cerritos, California, United States

and more 217 locations

PALACE: Cemiplimab Trial According to ctDNA Levels

Phase 2
Not yet recruiting
Conditions
Non Small Cell Lung Cancer Metastatic
Lung Diseases
Stage IV Non-small Cell Lung Cancer
Stage III Non-small Cell Lung Cancer
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions
First Posted Date
2025-04-08
Last Posted Date
2025-04-08
Lead Sponsor
Fundación GECP
Target Recruit Count
63
Registration Number
NCT06917573
Locations
🇪🇸

Hospital General de Valencia, Valencia, Spain

🇪🇸

Hospital General de Elche, Elche, Alicante, Spain

🇪🇸

ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain

and more 17 locations

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Phase 3
Not yet recruiting
Conditions
Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma
Ovarian Cancer
Fallopian Tube Cancer
Interventions
Drug: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
First Posted Date
2025-04-07
Last Posted Date
2025-05-08
Lead Sponsor
Imunon
Target Recruit Count
500
Registration Number
NCT06915025

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 2
Not yet recruiting
Conditions
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Nodal Marginal Zone Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Interventions
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Multigated Acquisition Scan
First Posted Date
2025-04-01
Last Posted Date
2025-04-01
Lead Sponsor
University of California, Davis
Target Recruit Count
25
Registration Number
NCT06905509
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy